Maze Therapeutics (NASDAQ:MAZE) CMO Sells $134,965.89 in Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CMO Harold Bernstein sold 5,189 shares of the firm’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total value of $134,965.89. Following the completion of the sale, the chief marketing officer directly owned 9,705 shares of the company’s stock, valued at $252,427.05. This represents a 34.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Harold Bernstein also recently made the following trade(s):

• On Wednesday, September 2nd, Harold Bernstein sold 5,106 shares of Maze Therapeutics stock. The stock was sold at an average price of $26.47, for a total value of $135,155.82.
• On Tuesday, September 1st, Harold Bernstein sold 16,141 shares of Maze Therapeutics stock. The shares were sold at an average price of $26.36, for a total value of $425,476.76.
• On Thursday, August 13th, Harold Bernstein sold 16,142 shares of Maze Therapeutics stock. The stock was sold at an average price of $27.61, for a total transaction of $445,680.62.
• On Wednesday, July 1st, Harold Bernstein sold 14,609 shares of Maze Therapeutics stock. The shares were sold at an average price of $29.90, for a total transaction of $436,809.10.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $26.21 on Monday. Maze Therapeutics, Inc. has a twelve month low of $14.27 and a twelve month high of $53.65. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The firm’s 50-day moving average is $28.69 and its two-hundred day moving average is $31.06.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, hitting the consensus estimate of ($0.76). On average, research analysts predict that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

MAZE has been the subject of several research reports. BTIG Research reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research note on Wednesday, August 12th. TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $66.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada boosted its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in Maze Therapeutics during the fourth quarter worth approximately $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in Maze Therapeutics in the 2nd quarter worth approximately $48,000. Finally, Russell Investments Group Ltd. raised its holdings in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares during the last quarter.

Trending Headlines about Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: Analyst sentiment remains broadly constructive. TD Cowen upgraded MAZE to “strong buy,” BTIG reiterated a “buy” rating with a $46 price target, and the consensus rating is “buy” with an average target of $66.00. Maze Therapeutics insider trading and analyst coverage
• Neutral Sentiment: Institutional ownership activity included purchases or position increases by Royal Bank of Canada, Russell Investments Group and other firms. These holdings are relatively small, however, and are unlikely to be a major near-term price driver.
• Neutral Sentiment: Maze’s CEO Jason Coloma, CMO Harold Bernstein and other insiders sold shares between September 1 and September 3. Combined reported sales totaled roughly $2.4 million, but the filings said the transactions were made to cover tax obligations from equity vesting; Bernstein’s September 1 sale was also conducted under a pre-arranged Rule 10b5-1 plan. SEC insider trading filing
• Negative Sentiment: The scale and repetition of insider selling may weigh on investor sentiment, particularly as the CEO reduced his directly held shares substantially. MAZE has also been trading below its 50-day and 200-day moving averages, signaling continued technical weakness. The company remains loss-making, with quarterly EPS of negative $0.76 and analysts expecting approximately negative $2.72 EPS for the year.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.